286 related articles for article (PubMed ID: 20061792)
1. Molecular vaccines for malaria.
Bruder JT; Angov E; Limbach KJ; Richie TL
Hum Vaccin; 2010 Jan; 6(1):54-77. PubMed ID: 20061792
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.
Halbroth BR; Sebastian S; Salman AM; Ulaszewska M; Gola A; Longley RJ; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2020 Jan; 88(2):. PubMed ID: 31740525
[TBL] [Abstract][Full Text] [Related]
3. Harnessing immune responses against Plasmodium for rational vaccine design.
Douradinha B; Doolan DL
Trends Parasitol; 2011 Jun; 27(6):274-83. PubMed ID: 21531627
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.
Collins WE; Pye D; Crewther PE; Vandenberg KL; Galland GG; Sulzer AJ; Kemp DJ; Edwards SJ; Coppel RL; Sullivan JS
Am J Trop Med Hyg; 1994 Dec; 51(6):711-9. PubMed ID: 7810803
[TBL] [Abstract][Full Text] [Related]
5. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.
Takala SL; Plowe CV
Parasite Immunol; 2009 Sep; 31(9):560-73. PubMed ID: 19691559
[TBL] [Abstract][Full Text] [Related]
6. Mixed allele malaria vaccines: host protection and within-host selection.
Barclay VC; Chan BH; Anders RF; Read AF
Vaccine; 2008 Nov; 26(48):6099-107. PubMed ID: 18804509
[TBL] [Abstract][Full Text] [Related]
7. Chimeric parasites as tools to study Plasmodium immunology and assess malaria vaccines.
Cockburn I
Methods Mol Biol; 2013; 923():465-79. PubMed ID: 22990798
[TBL] [Abstract][Full Text] [Related]
8. Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.
Saxena AK; Wu Y; Garboczi DN
Eukaryot Cell; 2007 Aug; 6(8):1260-5. PubMed ID: 17557884
[No Abstract] [Full Text] [Related]
9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
11. Dendritic Cell Responses and Function in Malaria.
Yap XZ; Lundie RJ; Beeson JG; O'Keeffe M
Front Immunol; 2019; 10():357. PubMed ID: 30886619
[TBL] [Abstract][Full Text] [Related]
12. Pre-erythrocytic malaria vaccines: identifying the targets.
Duffy PE; Sahu T; Akue A; Milman N; Anderson C
Expert Rev Vaccines; 2012 Oct; 11(10):1261-80. PubMed ID: 23176657
[TBL] [Abstract][Full Text] [Related]
13. Vaccination against malaria: targets, strategies and potentiation of immunity to blood stage parasites.
Taylor-Robinson AW
Front Biosci; 2000 Jan; 5():E16-29. PubMed ID: 10702381
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
15. Naked DNA for malaria vaccines.
Fricker J
Mol Med Today; 1996 Mar; 2(3):91. PubMed ID: 8846464
[No Abstract] [Full Text] [Related]
16. Designing malaria vaccines to circumvent antigen variability.
Ouattara A; Barry AE; Dutta S; Remarque EJ; Beeson JG; Plowe CV
Vaccine; 2015 Dec; 33(52):7506-12. PubMed ID: 26475447
[TBL] [Abstract][Full Text] [Related]
17. Orally delivered malaria vaccines: not too hard to swallow.
Wang L; Webster DE; Wesselingh SL; Coppel RL
Expert Opin Biol Ther; 2004 Oct; 4(10):1585-94. PubMed ID: 15461570
[TBL] [Abstract][Full Text] [Related]
18. Malaria vaccine development using synthetic peptides as a technical platform.
Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
[TBL] [Abstract][Full Text] [Related]
19. The path of malaria vaccine development: challenges and perspectives.
Arama C; Troye-Blomberg M
J Intern Med; 2014 May; 275(5):456-66. PubMed ID: 24635625
[TBL] [Abstract][Full Text] [Related]
20. Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
Westerfeld N; Pluschke G; Zurbriggen R
Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):50-7. PubMed ID: 17131241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
